Home › Acute myeloïde leukemie › Californië › Los Angeles
Acute myeloïde leukemie klinische studies in Los Angeles, CA
24 studies voor Acute myeloïde leukemie zoeken deelnemers op locaties in en rond Los Angeles (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- Cedars-Sinai Medical Center, Los Angeles
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Cedars-Sinai Medical Center, Los Angeles
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Cedars-Sinai Medical Center, Los Angeles
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Cedars-Sinai Medical Center, Los Angeles
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruterenFase 3
- Children's Hospital Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Mattel Children's Hospital UCLA, Los Angeles
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RekruterenFase 2
- USC Norris Comprehensive Cancer Center, Los Angeles
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruterenFase 2
- UCLA Medical Center, Los Angeles
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
RekruterenFase 3
- US-Los Angeles CA-UCLA, Los Angeles
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
RekruterenFase 3
- US-Los Angeles CA-UCLA, Los Angeles
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruterenFase 1/2
- Children's Hospital Los Angeles, Los Angeles
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruterenFase 3
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles, Los Angeles
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruterenFase 1
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Health - Bowyer Oncology Center, Los Angeles
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
RekruterenFase 3
- University of California Los Angeles (UCLA) - David Geffen School of Medicine, Los Angeles
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruterenFase 2
- UCLA Department of Medicine, Los Angeles
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruterenObservatieonderzoek
- UCLA, Los Angeles
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
RekruterenObservatieonderzoek
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruterenFase 2/3
- Keck School of Medicine of USC, Los Angeles
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruterenFase 1
- USC / Norris Comprehensive Cancer Center, Los Angeles
- UCLA - Bowyer Oncology Center, Los Angeles
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RekruterenFase 1
- UCLA, Los Angeles
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruterenFase 1
- University of California Los Angeles, Los Angeles
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RekruterenFase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
RekruterenFase 1
- UCLA Medical Center, Los Angeles
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
RekruterenFase 2
- UCLA Medical Center, Los Angeles
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RekruterenFase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Acute myeloïde leukemie studies in andere steden
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Andere studies in Los Angeles
- Niet-kleincellige longkanker87 studies
- Kanker (alle vormen)74 studies
- Borstkanker73 studies
- Prostaatkanker61 studies
- Colorectale kanker59 studies
- Metastatische kanker57 studies
- Eierstokkanker50 studies
- Longkanker45 studies
- Plaveiselcelcarcinoom van hoofd en hals42 studies
- Aldermeesklierkanker35 studies
- Endometriumkanker34 studies
- Melanoom34 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.